Overview

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

Status:
RECRUITING
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.
Phase:
PHASE2
Details
Lead Sponsor:
Immunovant Sciences GmbH